Bristol Myers Squibb (BMS) received U.S. Food and Drug Administration (FDA) approval for label updates for its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) to treat large B cell lymphoma (LBCL) and other lymphomas, and Abecma (idecabtagene vicleucel; ide-cel) to treat multiple myeloma.  These label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product was in...